Command Palette

Search for a command to run...

Clinical Trials · NCT01455870

A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes

CompletedPhase 3Exenatide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Intarcia Therapeutics
Enrollment
535
Start date
May 2013
Locations
54 sites, 5 countries
Primary endpoint
Change in HbA1c between Week 52 and Day 0
View Exenatide compound reference